Fri, Jul 25, 2014, 9:23 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

  • mnecklstring mnecklstring Oct 18, 2007 7:28 AM Flag

    Isis Adds New Drug to Its Development Pipeline

    Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
    Thursday October 18, 7:00 am ET


    CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that acts in the kidney to increase glucose excretion, complements Isis' existing pipeline of drugs in development for the treatment of diabetes, each of which act upon targets in the liver through distinct mechanisms to improve insulin sensitivity, reduce glucose production, or affect other metabolic aspects of this complex disease

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ISIS
30.14-0.48(-1.57%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.